Epizyme
IPOTransformative therapies against novel epigenetic targets
Public · Cambridge, United States · Founded 2007 · $154.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 201–500
- Founded
- 2007
- Business Model
- B2B
- Website
- epizyme.com
- Total Funding
- $154.0M
- Last Round
- $100.0M Growth EquityNov 2019
- Rounds
- 3
- Type
- Public
About
Epizyme is a commercial-stage biopharmaceutical company creating innovative drugs for major diseases based on epigenetics discoveries. It developed therapies targeting epigenetic targets for cancer and was acquired by Ipsen.
Summary
Epizyme is a Biotech company based in Cambridge, United States, founded in 2007. It has raised $154.0M in total across 3 rounds, most recently a $100.0M Growth Equity round in Nov 2019. Investors include Royalty Pharma, Bay City Capital and MPM Capital.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2019
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...